Protagonist Therapeutics price target raised to $116 from $104 at Clear Street

Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $116 from $104 and keeps a Buy rating on the shares. Following management meetings, the firm came away “incrementally more constructive” and sees Icotyde emerging as “a potential best-in-class option in chronic indications,” the analyst tells investors.